Uzbekistan Medical Device Registry: 6,572 Approvals & Entry Trends

A data-driven analysis of Uzbekistan's Uzpharm State Register. Discover registration volumes, product categories, and leading foreign suppliers.

Uzbekistan’s healthcare sector is undergoing a massive modernization campaign, driven by ambitious government reforms and public infrastructure investment. However, with domestic production meeting only a fraction of local demand, the market remains highly dependent on foreign imports. To successfully navigate this expanding market, regulatory affairs managers and business development teams need objective, quantitative data on the existing competitive landscape.

This article provides a comprehensive teardown of the Uzbekistan State Register of Medicines and Medical Devices (specifically Version N30, published by the Agency for Development of the Pharmaceutical Industry on June 15, 2026). By analyzing manufacturer countries of origin, product classification distributions, and leading foreign suppliers, we outline key commercial trends and regulatory requirements under the newly active Cabinet of Ministers Resolution No. 738.

For broader regional context on registration systems in neighboring CIS markets, consult our comprehensive EAEU medical device registration guide to understand how Uzbekistan’s national framework compares to the nearby Eurasian Economic Union bloc.

What is the volume and distribution of medical devices in Uzbekistan's State Register?

An analysis of the compiled Uzpharm State Register reveals a total of 6,572 registered medical product records. The registry shows an exceptionally high rate of active listings, indicating that the vast majority of historical approvals remain commercially valid:

Active Registrations: 6,569 records (99.95%)
Cancelled Registrations: 3 records (0.05%)

This high ratio of active registrations suggests that manufacturers view Uzbekistan as a long-term market and actively maintain their marketing authorizations.

Product Category Distribution

Under the Uzbekistan regulatory framework, products are broadly divided into two major record types: general medical equipment and products, and in vitro diagnostic (IVD) medical devices. The volume of approvals is heavily weighted toward general equipment:

Product Category	Number of Records	Percentage of Registry	Description
Medical Equipment or Product	5,505	83.76%	Active medical devices, surgical instruments, implants, consumables, and general hospital hardware.
In Vitro Diagnostic (IVD) Medical Device	1,064	16.19%	Diagnostic reagents, test kits, calibrators, controls, and laboratory analyzers.
Cancelled Medical Device or Equipment	3	0.05%	Historically revoked or withdrawn registrations.
Total	6,572	100.00%	Comprehensive medical registry database.

This distribution reflects a market that has historically prioritized establishing basic clinical infrastructure—such as patient monitors, imaging systems, and surgical tools—while IVD testing capacities represent a smaller, though rapidly growing, segment of the market.

Which foreign countries dominate the medical device supply chain to Uzbekistan?

Uzbekistan’s medical device market is almost entirely supplied by international manufacturers, with imports accounting for approximately 90% of all active registrations. An aggregation of registrations by the manufacturer's country of origin reveals a clear geographic distribution:

Rank	Country of Origin	Number of Approvals	Percentage of Registry	Key Segments & Focus
1	China	1,736	26.41%	High-volume consumables, rapid test kits, patient monitoring, and ultrasound equipment.
2	Russia	671	10.21%	IVD reagents, laboratory diagnostics, and CIS-focused medical instruments.
3	Uzbekistan (Domestic)	561	8.54%	Basic single-use consumables, bandages, syringes, and local assembly lines.
4	United States	557	8.47%	Premium imaging equipment, high-risk active implants, and advanced surgical tools.
5	Germany	554	8.43%	High-end clinical laboratory systems, dental equipment, and premium surgical hardware.
6	South Korea	413	6.28%	Aesthetic devices, laser systems, digital imaging, and rapid point-of-care diagnostics.
7	India	236	3.59%	Generic hospital supplies, surgical sutures, and cost-effective clinical instruments.
8	Italy	233	3.55%	Dental hardware, clinical furniture, and specialized rehabilitation equipment.
9	Japan	207	3.15%	High-resolution endoscopes, premium ophthalmology systems, and advanced imaging.
10	Turkey	126	1.92%	Hospital sterilization systems, operating room setups, and orthopedic implants.
11	Switzerland	111	1.69%	Precision orthopedic implants, high-end dental components, and specialized laboratory software.
12	Spain	105	1.60%	Clinical chemistry reagents, diagnostic equipment, and physical therapy hardware.

Analysis of Foreign Dominance

The Chinese Market Surge

Chinese manufacturers command more than a quarter of the entire Uzbekistan medical device registry with 1,736 approvals. This dominance is driven by a combination of aggressive pricing, broad product portfolios, and strong bilateral trade support under the "Belt and Road" initiative. Chinese companies have successfully captured high-volume clinical segments, particularly in patient monitoring, ultrasound imaging, and rapid in-vitro diagnostic test kits.

Russian Regional Integration

Russia remains the second-largest foreign supplier with 671 registrations. This presence is highly concentrated in in-vitro diagnostics and laboratory reagents. The close proximity, shared CIS technical standards, and widespread use of the Russian language in clinical and regulatory filings significantly lower entry barriers for Russian manufacturers compared to Western European or American firms.

The Premium Western Tier (US and Germany)

The United States (557 approvals) and Germany (554 approvals) are virtually tied in their market representation. Unlike Chinese and Russian suppliers who focus on high-volume consumables and diagnostics, American and German manufacturers dominate the high-value, technologically complex segments. These include magnetic resonance imaging (MRI) systems, computed tomography (CT) scanners, active implantable cardioverter-defibrillators (AICDs), and advanced ophthalmic surgical suites.

South Korea's Aesthetic Foothold

With 413 approvals, South Korea has carved out a highly profitable niche in Uzbekistan. South Korean registrations are heavily weighted toward aesthetic medicine—including laser skin treatment systems, dermal fillers, and cosmetic surgical tools—as well as digital radiography and rapid diagnostic testing.

Who are the leading manufacturers registered under Uzpharm?

An examination of manufacturer concentrations reveals that a handful of major multinational corporations and specialized CIS developers hold a significant share of the register. The top manufacturers registered under Uzpharm include:

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China): 151 registrations. Mindray is by far the most dominant single manufacturer in Uzbekistan. Its registered portfolio spans patient monitoring, life support systems, in-vitro diagnostic instruments, and medical imaging.
Vector-Best, AO (AO "Вектор-Бест", Russia): 66 registrations. This major Russian developer is highly specialized in ELISA and real-time PCR diagnostic kits, representing a significant portion of Uzbekistan's clinical laboratory testing capacity.
Cypress Diagnostics (Belgium): 47 registrations. Cypress focuses on clinical chemistry reagents, hematology analyzers, and rapid laboratory test kits tailored for small-to-medium diagnostic labs.
Rossa, ООО (Russia): 45 registrations. Specialized in general clinical supplies, reusable instruments, and diagnostic accessories.
BioSystems S.A. (Spain): 41 registrations. Spain’s leading clinical chemistry and immunochemistry systems developer.
Guangzhou Wondfo Biotech Co., Ltd. (China): 40 registrations. A leading developer of point-of-care testing (POCT) and rapid immunoassay kits.
Health Line, СП ООО (Uzbekistan): 40 registrations. A key domestic joint venture manufacturing sterile single-use medical products, including syringes, IV sets, and surgical gloves.
Assure Tech (Hangzhou) Co., Ltd. (China): 39 registrations. Focused on rapid lateral flow tests, infectious disease screening, and toxicology test kits.
Shenzhen Comen Medical Instruments Co., Ltd. (China): 39 registrations. Focused on neonatal care, electrophysiology, and intensive care monitoring.
Roche Diagnostics GmbH (Germany/Switzerland): 38 registrations. High-throughput laboratory diagnostics, molecular analyzers, and premium tissue diagnostics.
Alcon Laboratories, Inc. (USA): 37 registrations. Premium ophthalmic surgical systems, intraocular lenses (IOLs), and ophthalmic solutions.
Bio-Rad Laboratories Inc. (USA): 37 registrations. Quality control systems, clinical laboratory instruments, and specialized reagents.

Strategic Implications for New Entrants

The concentration of registrations among these top-tier manufacturers reveals that the Uzbekistan market is highly consolidated in standard clinical categories. For instance, a new manufacturer entering the general patient monitoring or basic rapid-testing space faces intense competition from established giants like Mindray (151 registrations) and Vector-Best (66 registrations).

To compete effectively, new market entrants should:

Identify Niche Gaps: Focus on highly specialized therapeutic areas (e.g., advanced neurovascular implants, specialized pediatric oncology tools, or high-throughput automated molecular diagnostics) where Mindray and regional players do not have a dominant footprint.
Leverage Simplified Recognition: Target products that already hold FDA or CE clearance to utilize the accelerated recognition pathway, avoiding the lengthy national registration procedure.
Localize Support: Invest in establishing local maintenance, training, and support capabilities in Tashkent, as local clinical training is a major competitive differentiator.

Detailed Step-by-Step Registration Procedure

Navigating the registration process in Uzbekistan requires a systematic approach. The timeline, complexity, and testing requirements depend heavily on the chosen registration pathway.

Pathway Comparison and Gating Steps

Below is a detailed comparison of the workflows for the two registration pathways in Uzbekistan:

Stage	Simplified Recognition Pathway	National Registration Pathway
Eligibility	Valid approval from FDA (US), CE (EU), PMDA (Japan), MFDS (Korea), or MHRA (UK).	No prior reference market approvals, or only approvals from non-recognized countries.
Step 1: Local Representation	Appoint an Authorized Representative (AR) registered in Uzbekistan.	Appoint an Authorized Representative (AR) registered in Uzbekistan.
Step 2: Dossier Preparation	Administrative documents, proof of reference approval, local labeling.	Technical file, design files, clinical data, manufacturing process files, local labeling.
Step 3: Submission & Fees	Submission to Uzpharm; pay evaluation fee (30–80+ BCV depending on risk class).	Submission to Uzpharm; pay evaluation fee (30–80+ BCV depending on risk class).
Step 4: IP Verification	Ministry of Justice check for trademark/packaging conflicts.	Ministry of Justice check for trademark/packaging conflicts.
Step 5: Sample Testing	Waived (No local laboratory testing of device samples required).	Mandatory shipment of samples to the Tashkent State Laboratory for physical and chemical testing.
Step 6: Evaluation	Document review and verification of reference certificates.	Comprehensive technical review, testing report evaluation, clinical audit.
Timeline	1 to 2 months	6 to 12 months
Outcome	5-Year Registration Certificate issued.	5-Year Registration Certificate issued.

Technical Documentation Requirements by Risk Class

The technical dossier structure must follow standard formats, with translating support in both Uzbek and Russian. Below is the minimum documentation matrix required for submissions:

Class I (Low Risk):
- Completed application form detailing manufacturer and importer legal names.
- Power of Attorney (notarized and apostilled/legalized) issued by the manufacturing site.
- Certificate of Free Sale (CFS) from the country of origin.
- ISO 13485 certification of the manufacturer (copy with notarized translation).
- Bilingual instructions for use (IFU) and outer packaging labels in both Uzbek and Russian.
- Basic technical datasheet (dimensions, materials, electrical safety specifications).
Class IIa & IIb (Medium Risk):
- All Class I documentation.
- Detailed risk management file (aligned with ISO 14971 guidelines).
- Manufacturing process flowchart showing critical steps, assembly, and quality control checks.
- Sterilization validation reports (for sterile devices, including EO or radiation sterilization details).
- Software verification and validation reports (if the device contains active software).
- Clinical evaluation report (CER) showing literature-based equivalence or clinical study summaries.
Class III (High Risk):
- All Class I and II documentation.
- Full clinical trial data (required for new-to-market technologies without CE/FDA reference).
- Detailed biocompatibility data (aligned with ISO 10993 parameters).
- Detailed safety and performance testing reports (e.g., IEC 60601-1 series from accredited labs).
- Post-market clinical follow-up (PMCF) plan and periodic safety update reports (PSUR).

Legal Risks and Distributor Management

One of the most critical business decisions when entering Uzbekistan is deciding who will hold the sanitary registration. Under Cabinet of Ministers Resolution No. 738, the registration certificate is held by the designated local Authorized Representative (AR).

The Problem of Distributor Ownership

Many foreign manufacturers choose to let their local commercial distributor act as their AR. While this saves initial administrative overhead, it introduces significant long-term business vulnerabilities:

Importation Blockades: Once a distributor holds the registration, they are the legal importer of record. If the distributor underperforms, or if the manufacturer wishes to appoint a second distributor, they must obtain a formal transfer signature from the original distributor.
Hostage Registrations: Uncooperative distributors may demand financial compensation to sign over the registration certificate to a new partner.
Blackout Risks: If the distributor refuses to cooperate, the manufacturer must cancel the registration and apply for a new one, resulting in a 6-to-12-month sales blackout during the standard national procedure.

The Independent Representative Solution

To maintain commercial flexibility, manufacturers are strongly advised to appoint an independent, third-party regulatory consultant in Tashkent to act as the neutral AR. Under this structure:

The neutral AR holds the registration certificate.
The manufacturer can authorize multiple, independent commercial distributors to import the product using the same registration certificate.
If a distributor relationship is terminated, the registration remains unaffected, and imports can continue through new partners without delay.

Customs Clearance and Importation Logistics in Tashkent

Once the sanitary registration certificate is secured, the next major milestone is managing physical imports through customs. The main port of entry for medical hardware is Tashkent International Airport or the Tashkent container rail terminals.

Step-by-Step Customs Workflow

Pre-Shipment Documentation Check: The importer of record must gather the following files before shipment arrival:
- Copy of the active Uzpharm Registration Certificate.
- Commercial Invoice showing product description, models, HS codes, unit price, and total value.
- Packing List showing weight, volumes, and box breakdown.
- Bill of Lading / Air Waybill.
- Certificate of Origin showing manufacturing location.
ASL BELGISI Traceability Verification: Under recent Uzbekistan digitalization decrees, certain medical device categories require unique traceability marking (similar to GS1 barcodes). The importer must register the codes in the ASL BELGISI national database before customs clearance.
VAT and Customs Duties Assessment: Under the Uzbekistan tax code:
- The standard Value Added Tax (VAT) rate is 12%.
- Customs duty rates depend on the specific HS code, ranging from 0% to 15%.
- Critical VAT Exemption: Specific medical equipment, diagnostics, and orthopedic components are exempt from the 12% VAT under Cabinet of Ministers decrees. The importer must submit the active Uzpharm certificate to the customs office to claim this exemption.
Physical Customs Inspection: Customs officers in Tashkent inspect the shipment. They check that the physical model numbers, manufacturer name, and manufacturing dates on the device packaging exactly match the details on the Uzpharm Registration Certificate. If there are typos, the shipment is blocked.
Release for Distribution: Upon verification and payment of customs fees (typically 0.2% of the customs value for administrative handling), the shipment is cleared and released to the importer's warehouse.

Comparison: Uzbekistan vs. EAEU Regulatory Systems

Although Uzbekistan is geographically surrounded by Eurasian Economic Union (EAEU) members (such as Kazakhstan and Kyrgyzstan) and participates as a non-member observer, it maintains a completely independent national regulatory framework.

Understanding the differences between these two systems is vital for regional compliance planning:

Regulatory Parameter	Uzbekistan National System	EAEU Regional System
Geographic Scope	territory of the Republic of Uzbekistan only.	Five member states (Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan).
Primary Regulator	Uzpharm (Ministry of Health).	Eurasian Economic Commission / National Ministries.
Simplified Recognition Pathway	Yes (Fast-track for FDA, CE, PMDA, MFDS, and MHRA).	No (All devices must undergo full EAEU technical/clinical audits).
Language Requirements	Uzbek and Russian.	Russian (dossier); Russian and national languages (labeling).
Dossier Format	National format (Resolution 738).	Harmonized EAEU format.
Typical Timelines	1–2 months (Recognition); 6–12 months (National).	12 to 24 months (Full EAEU review).
GMP Audits	Paper review / Local testing based on risk.	Mandatory regional EAEU GMP site audits for Class IIa/IIb/III.
Registry Database	Uzpharm State Register.	Unified Registry of the Eurasian Economic Commission.

Strategic Recommendations for Market Access

To establish a successful commercial footprint in Uzbekistan's medical device market, manufacturers should structure their entry strategy around the following three pillars:

1. Carefully Select a Local Authorized Representative

Because the registration certificate is held by the local Authorized Representative (AR), foreign manufacturers must select their local partner with care. Transitioning a registration to a new importer can be extremely difficult if the relationship sours, as it requires the signature of the existing certificate holder. For high-value medical hardware, it is often safer to contract a neutral, third-party regulatory consultant in Tashkent to act as the independent AR, allowing the manufacturer to work with multiple independent distributors.

2. Maintain a Dual-Language Documentation Strategy

Uzbekistan is a bilingual market. While Russian remains the primary language of technical communication and engineering in clinical settings, the official language is Uzbek. All user manuals, instructions for use (IFUs), patient-facing labels, and outer packaging must be bilingual (Russian and Uzbek) to pass the final State Centre compliance audit. Ensuring high-quality, professional translations early in the dossier compilation stage prevents costly delays during the review phase.

3. Account for Intellectual Property Clearance

Under Resolution No. 738, the Ministry of Justice's IP check is a formal gating step. Manufacturers should conduct a preliminary trademark search in the national database of the Intellectual Property Agency of Uzbekistan before submitting their registration dossier. Confirming that your brand name, logo, or product design does not conflict with local registered trademarks prevents sudden rejections based on IP compliance.

Frequently Asked Questions (FAQ)

What regulator oversees medical device registration and the State Register in Uzbekistan?

The registration of medical devices is overseen by the State Center for Expertise and Standardization of Medicines, Medical Devices, and Medical Equipment under the Agency for Development of the Pharmaceutical Industry (Uzpharm), which functions under the Ministry of Health of the Republic of Uzbekistan.

How many registered medical devices in Uzbekistan are classified as In Vitro Diagnostics (IVD)?

According to the Uzpharm registry, there are 1,064 registered in vitro diagnostic (IVD) medical devices, representing 16.19% of the total medical product database. The remaining 5,505 records (83.76%) are classified as general medical equipment and products.

What is the validity period of an Uzbekistan registration certificate?

A medical device registration certificate issued by Uzpharm is valid for 5 years. Applications for renewal must be submitted at least three months before the certificate's expiration date to avoid commercial disruption.

Can a foreign manufacturer apply for registration directly?

No. Foreign manufacturers must appoint an Authorized Representative (AR) that is a legally registered company within the Republic of Uzbekistan to submit the application and act as the primary liaison with the regulatory authorities.

Does Uzbekistan recognize CE marking or US FDA clearance?

Yes. Under the simplified recognition pathway established by Resolution No. 738, devices that already hold valid regulatory approvals from the US FDA, EU (CE Mark), Japan (PMDA), South Korea (MFDS), or United Kingdom (MHRA) can bypass local laboratory testing. This reduces the registration timeline from the standard 6–12 months down to 1–2 months.

What is the fee structure for registrations under the 2026 rules?

Fees are calculated in Basic Calculated Values (BCV). Since August 1, 2025, the BCV has been set at 412,000 UZS (roughly $33 USD), so evaluation fees work out to roughly 30 BCVs (~$990 USD) for Class I, 67 BCVs (~$2,211 USD) for Class IIa/IIb, and 80+ BCVs (~$2,640+ USD) for Class III devices. These are indicative figures based on the Resolution No. 738 fee framework; confirm the current schedule with Uzpharm before budgeting, as the exact multiplier varies with risk class and dossier type.

What is the standard VAT rate for imported medical devices?

The standard VAT rate is 12%. However, specific medical equipment and devices registered under the Uzpharm database are eligible for a 12% VAT exemption upon presenting a valid Uzpharm certificate.

Sources

State Register of Medicines and Medical Devices (Version N30): Published by the Agency for Development of the Pharmaceutical Industry under the Ministry of Health of the Republic of Uzbekistan (Uzpharm), June 15, 2026.
Cabinet of Ministers Resolution No. 738: "On Measures to Regulate the State Registration of Medicines and Medical Devices," dated November 24, 2025; effective February 26, 2026.
Decree of the President of the Republic of Uzbekistan (No. UP-137): "On Additional Measures to Regulate the Circulation of Medicines and Medical Devices" (August 19, 2025), the presidential decree that Resolution No. 738 implements.
State Center for Expertise and Standardization of Medicines, Medical Devices, and Medical Equipment: Official regulatory guidance portal, accessed June 2026 (https://www.uzpharm-control.uz).